ORGANON & CO (OGN)
US68622V1061 - Common Stock
7 Sleeper Stocks to Buy Before Wall Street Wakes Up: April 2024
While these sleeper stocks to buy don’t attract the spotlight, the lack of attention makes these ideas even more enticing.
3 Healthcare Stocks With the Potential to Triple Your Investment by 2026
Learn how these three healthcare stocks offer sharp opportunities in pharmaceuticals, healthcare services, and biotechnology.
Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
YieldBoost OGN From 6.1% To 21.1% Using Options
On International Women's Day, Organon Canada is encouraging businesses to Invest in HER and help address gender inequities through women's health
/CNW/ - On International Women's Day, Organon Canada, a subsidiary of Organon (NYSE: OGN), a global healthcare company with a focus on women's health, launches...
Turn $500 into a Fortune: 3 Top Stock Picks for March’s Million-Dollar Rally
Here are three top stock picks for rally have their grip in travel, packaged foods, meats and pharmaceuticals.
Drug Maker Organon Stock Scores Relative Strength Upgrade
In a welcome move, drug maker Organon stock saw its Relative Strength Rating rise from 66 to 71 on Wednesday.
Grab This Deal Even Lower Than Gen. Counsel & Corp. Secy. Weaver Did
Under the Radar: 3 Overlooked Stocks Ready to Dominate the Market
Explore growth strategies of overlooked stocks with strong fundamentals in strategic investments and market expansion.
Organon stock nears five-month high after Q4 beat (NYSE:OGN)
Organon (OGN) stock spikes as the women's healthcare company beats Q4 2023 expectations and offers in-line guidance for 2024. Read more here.
OGN Crosses Above Key Moving Average Level
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023
Organon stock on the rise ahead of Q4 earnings (NYSE:OGN)
Organon (OGN) is gaining positive ciew on Wall Street, and its share price is rising ahead of its Q4 2023 results on Thursday, before the opening bell. Read more here.
Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 15, 2024
Organon & Co. set to break its six-day losing streak (NYSE:OGN)
SA contributor, Gen Alpha said, the company has faced challenges in its women's health segment but expects a turnaround in its top-selling drug and growth in th
Organon says Xaciato now available nationwide (NYSE:OGN)
Organon (OGN) said that Xaciato, a formulation of clindamycin phosphate, is now available nationwide for the treatment of bacterial vaginosis in females aged 12
Organon expects revenue to grow in the low-single-digit range for FY24 (NYSE:OGN)
Organon expects stable to improving Adjusted EBITDA margin and low-single-digit revenue growth in 2024, while projecting higher free cash flow for 2023.
